Table 3.

Unadjusted and adjusted hazard ratio for primary outcome

Variables	Univariate analysis			Multivariate analysis
	Hazard ratio	95% CI	P value	Hazard ratio	95% CI	P value
Spironolactone	0.62	0.44–0.87	0.005	0.63	0.44–0.90	0.010
Age (≥70 years)	1.73	1.26–2.36	<0.001	1.56	1.10–2.21	0.012
Male	1.02	0.74–1.38	0.93	0.95	0.67–1.34	0.76
Previous HF admission	3.20	2.30–4.39	<0.001	2.59	1.84–3.65	<0.001
NYHA III–IV at discharge	2.22	1.20–4.10	0.011	1.70	0.90–3.23	0.10
Smoking	0.96	0.70–1.32	0.79
SBP (per 10 mmHg), mmHg	0.99	0.91–1.08	0.84
LVEF (per 10%), %	1.52	0.89–2.60	0.13
LVDd (per 10 mm), mm	0.89	0.73–1.07	0.21
LVDs (per 10 mm), mm	0.89	0.72–1.11	0.30
Hypertension	1.05	0.77–1.42	0.77
Diabetes mellitus	1.16	0.85–1.59	0.35
Dyslipidaemia	1.04	0.75–1.45	0.82
Chronic kidney disease	2.70	1.89–3.86	<0.001	1.98	1.29–3.04	0.002
Hyperuricemia	1.35	0.99–1.83	0.055
Stroke	1.34	0.91–1.98	0.14
Anaemia	1.67	1.18–2.36	0.004	0.95	0.63–1.45	0.82
COPD	1.71	0.99–2.96	0.054
Ischaemic heart disease	1.45	1.07–1.97	0.015	0.84	0.60–1.17	0.30
Previous PCI	1.24	0.87–1.78	0.24
Previous CABG	1.31	0.85–2.01	0.23
Chronic AF, AFL	1.08	0.79–1.49	0.64
Sustained VT, VF	2.36	1.41–3.97	0.001	2.12	1.24–3.62	0.006
ACE‐I or ARB	0.71	0.50–1.02	0.065
Beta‐blocker	0.92	0.68–1.24	0.58
Thiazide	1.07	0.40–2.87	0.90
Loop diuretics	1.16	0.80–1.68	0.43
Nitrate	1.24	0.89–1.74	0.21
Digitalis	0.91	0.65–1.28	0.60
Oral inotrope	1.76	1.05–2.95	0.032	1.64	0.93–2.89	0.087
Aspirin	0.98	0.73–1.33	0.90
Warfarin	0.66	0.48–0.92	0.014	0.79	0.55–1.14	0.21
Statin	0.91	0.63–1.31	0.60

Abbreviations as in Table 1. CI, confidence interval; HR, hazard ratio.